Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). High-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years.


Clinical Trial Description

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). High-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years. If at least one HHC within a household (HH) is found to be eligible, the HH will be randomized to one of the following: Arm A: DLM daily for adults, adolescents, and children, given for 26 weeks. Arm B: INH daily for adults, adolescents, and children, given for 26 weeks AND pyridoxine (vitamin B6) daily for adults, adolescents, and children, given for 26 weeks. All high-risk HHCs in the same HH will receive the same randomized regimen. All participants will be in the study for 96 weeks. At study entry, index cases will undergo a medical history review and sputum collection. HHCs will have study visits at study entry and at Weeks 2, 4, 8, 12, 16, 20, 26, 36, 48, 60, 72, 84, and 96. Visits may include physical examinations; blood, urine, and sputum collection; electrocardiograms (ECGs); and questionnaires and assessments. Forty HHCs under the age of 5 taking DLM will undergo an intensive PK visit at Week 8. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03568383
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Recruiting
Phase Phase 3
Start date June 3, 2019
Completion date July 30, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT03086486 - Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Phase 3
Not yet recruiting NCT06441006 - Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Phase 3
Recruiting NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Phase 2
Completed NCT03338621 - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Phase 2/Phase 3
Completed NCT02607449 - FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis Phase 3